Mefenamic Acid
- Chemical Name: Mefenamic acid
- CAS No.: 61-68-7
- MF: C15H15NO2
- MW: 241.29
- Purity: ≥98% or according to customer requested
- Color: Light Yellow
- Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;APIs
- Test method: HPLC
Description
What is Mefenamic acid?
Mefenamic acid is an aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor.
It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. It has a role as an analgesic, an antirheumatic drug, a non-steroidal anti-inflammatory drug, an antipyretic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an environmental contaminant and a xenobiotic. It is an aminobenzoic acid and a secondary amino compound.
Product Name: | Mefenamic acid |
Synonyms: | Mefenamic Acid (200 mg); Mefenamic acid Solution; MefenaMic Aicd (API); Mephenamic acid; Methenamic acid; Mephenaminic acid; Mefanamic acid |
CAS: | 61-68-7 |
MF: | C15H15NO2 |
MW: | 241.29 |
EINECS: | 200-513-1 |
Product Categories: | Intermediates & Fine Chemicals; Pharmaceuticals; APIs; Antipyretic analgesics; NSAIDS |
Melting point | 230 °C |
Boiling point | 384.06°C (rough estimate) |
density | 1.0944 (rough estimate) |
refractive index | 1.5200 (estimate) |
storage temp. | 2-8°C |
solubility | Practically insoluble in water, slightly soluble in ethanol (96 per cent) and in methylene chloride. It dissolves in dilute solutions of alkali hydroxides |
form | neat |
pka | 4.2(at 25℃) |
Water Solubility | It is soluble in acetone, chloroform, dichloromethane, methanol. Insoluble in water. |
Mefenamic Acid is an anthranilic acid and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Mefenamic acid inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of mefenamic acid. Mefenamic acid also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. It is used largely for acute treatment of pain. Mefanamic acid has been linked to rare instances of clinically apparent, acute liver injury.
Technical Support & Resources
Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
MSDS: MSDS available.
COA: COA can be available if you send us inquiry.
Email us at: info@maxmedchem.com for more details.